@Transplant_Doc @BloodJournal @MichaelDJain https://t.co/e5KOjrlNWf

@michaelwangmd Dr. Wang, check out Dr. Mark Geyer’s w/MSK study of novel ARC lymphodepletion prior to CAR-T as the promising solution to this problem. (NCT04512716). https://t.co/e5KOjrlNWf

$ATNM Iomab-ACT targeted lymphodepletion using ARCs prior to CAR-T and gene therapies - Promising data shows reduction in CRS and neurotoxicity. Currently being studied in phase 1/2 trial. https://t.co/e5KOjrlNWf

@MSubklewe @MarkGeyerMD @Daver_Leukemia This is a great source with data and additional references https://t.co/e5KOjrlNWf

Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy. by Dawicki W, Allen KJH, Garg R, Geoghegan EM, Berger MS, Ludwig DL, Dadachova E https://t.co/qGE3CGNssP